These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20598799)

  • 1. Re: Monique J. Roobol, Ewout W. Steyerberg, Ries Kranse, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010;57:79-85.
    Morrod D
    Eur Urol; 2010 Sep; 58(3):327; author reply 328-30. PubMed ID: 20598799
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Monique J. Roobol, Fritz H. Schröder, Pim van Leeuwen, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010;58:475-81.
    Connolly D; Hutton R; Keane PF
    Eur Urol; 2011 Mar; 59(3):e9; author reply e10-1. PubMed ID: 21145647
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99.
    Stephan C; Schnorr D; Loening SA; Jung K
    Eur Urol; 2005 Dec; 48(6):1059-60; author reply 1060-1. PubMed ID: 16260082
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
    Stamatiou K; Alevizos A; Mariolis A; Sofras F
    J Urol; 2006 Sep; 176(3):1251-2; author reply 1252. PubMed ID: 16890735
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. S. E. Eggener, K. A. Roehl, O. Yossepowitch and W. J. Catalona, J Urol 2006; 176: 1399-1403.
    Wagner MD; Daneshmand S; Sokoloff M; Barry JM
    J Urol; 2007 Jun; 177(6):2396; author reply 2396-7. PubMed ID: 17509368
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer: I. M. Thompson, D. P. Ankerst, R. Etzioni and T. Wang J Urol 2008; 180: 1219-1222.
    Walsh PC
    J Urol; 2009 Mar; 181(3):1499; author reply 1499-500. PubMed ID: 19157429
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Michael L. Eisenberg, Benjamin J. Davies, Matthew R. Cooperberg, et al. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2010;57:622-30.
    Ost P; Bossi A; De Meerleer G
    Eur Urol; 2010 Sep; 58(3):e33; author reply e34-5. PubMed ID: 20537787
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol 2021;80:703-711: Would You Play a Russian Roulette-type Game of Prostate-specific Antigen Screening on Yourself?
    Takahashi T
    Eur Urol; 2022 Jan; 81(1):e22. PubMed ID: 34716050
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial: R. M. Stopiglia, U. Ferreira, M. M. Silva, W. E. Matheus, f. Denardi and L. O. Reis J Urol 2010; 183: 940-945.
    Yoon DK; Park HS; Park JY
    J Urol; 2010 Nov; 184(5):2214-5; author reply 2215. PubMed ID: 20864135
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Takeshi Takahashi's Letter to the Editor re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol 2021;80:703-711: Would You Play a Russian Roulette-type Game of Prostate-specific Antigen Screening on Yourself?
    Van Poppel H; Roobol MJ
    Eur Urol; 2022 Jan; 81(1):e23-e24. PubMed ID: 34756628
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Felix K.-H. Chun, Thomas Steuber, Andreas Erbersdobler, et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 2006;49:820-26.
    Beckley I; Khan MA
    Eur Urol; 2007 Oct; 52(4):1270; author reply 1271. PubMed ID: 17611016
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Martin Spahn, Steven Joniau, Paolo Gontero, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 2010;58:1-7.
    Neulander EZ; Wejsman Z
    Eur Urol; 2010 Sep; 58(3):e36; author reply e37-8. PubMed ID: 20605673
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: E. David Crawford, Per-Anders Abrahamsson. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 2008;54:262-73.
    Kvåle R; Hernes E; Bray F
    Eur Urol; 2009 May; 55(5):e88-9; author reply e90-1. PubMed ID: 19062155
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Zhao et al.: External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment Score (Urology 2008;72:396-400).
    Stephenson AJ
    Urology; 2008 Sep; 72(3):719-20. PubMed ID: 18762055
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. S. Baltaci, E. Suer, A. H. Haliloglu, M. I. Gokce, A. H. Elhan and Y. Beduk. J Urol 2009; 181: 128-132.
    Eggener SE; Raman JD
    J Urol; 2009 Jul; 182(1):396-7. PubMed ID: 19467675
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Felix K.-H. Chun, Markus Graefen, Alberto Briganti, Andrea Gallina, Julia Hopp, Michael W. Kattan, Hartwig Huland and Pierre I. Karakiewicz. Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol 2007;51:1236-43.
    Stephan C; Meyer HA; Cammann H; Lein M; Loening SA; Jung K
    Eur Urol; 2007 May; 51(5):1446-7; author reply 1448. PubMed ID: 17141943
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostatic cancer. Eur Urol 2003;44:512-8.
    Tubaro A; De Nunzio C
    Eur Urol; 2004 May; 45(5):674; author reply 674-5. PubMed ID: 15082213
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9.
    Ragavan N; Singh PB; Martin FL; Baird AD
    Eur Urol; 2009 Feb; 55(2):e43-4. PubMed ID: 18771846
    [No Abstract]   [Full Text] [Related]  

  • 19. Androgen Deprivation (AD) among low-risk and intermediate-risk prostate cancer patients: in regard to Ciezki et al. (Int J Radiat Oncol Biol Phys 2004;60:1347-1350).
    Oton CA
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):291-2; author reply 292. PubMed ID: 15850937
    [No Abstract]   [Full Text] [Related]  

  • 20. Upcoming evidences on prostate-specific antigen-based screening for men at risk of prostate cancer.
    Boscolo-Berto R
    Int J Urol; 2009 Sep; 16(9):711. PubMed ID: 19769655
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.